Loading
A phase 2 trial of MMB in myeloproliferative neoplasms, run by GlaxoSmithKline, active and no longer recruiting.
Extended Access of Momelotinib in Adults With Myelofibrosis is a phase 2 interventional study registered as NCT03441113 by GlaxoSmithKline, with 237 participants enrolled, started 2018-05-03 and due to reach its primary completion in 2026-12-11. Interventions recorded: MMB.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares GSK and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/